Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial
在资源匮乏地区，包括拉替拉韦 (RAL)、达芦那韦 (DRV/r) 和/或依曲韦林 (ETR) 在内的三线抗逆转录病毒疗法耐受性良好，并可在 144 周内实现持久的病毒学抑制：ACTG A5288 策略试验
期刊:Journal of the International Aids Society
影响因子:4.9
doi:10.1002/jia2.25905
Avihingsanon, Anchalee; Hughes, Michael D; Salata, Robert; Godfrey, Catherine; McCarthy, Caitlyn; Mugyenyi, Peter; Hogg, Evelyn; Gross, Robert; Cardoso, Sandra W; Bukuru, Aggrey; Makanga, Mumbi; Badal-Aesen, Sharlaa; Mave, Vidya; Ndege, Beatrice Wangari; Fontain, Sandy Nerette; Samaneka, Wadzanai; Secours, Rode; Van Schalkwyk, Marije; Mngqibisa, Rosie; Mohapi, Lerato; Valencia, Javier; Sugandhavesa, Patcharaphan; Montalban, Esmelda; Munyanga, Cornelius; Chagomerana, Maganizo; Santos, Breno R; Kumarasamy, Nagalingeswaran; Kanyama, Cecilia; Schooley, Robert T; Mellors, John W; Wallis, Carole L; Collier, Ann C; Grinsztejn, Beatriz
